Registrar Corp Registrar Corp LinkedIn Registrar Corp Twitter Registrar Corp Facebook Registrar Corp Google+ Registrar Corp Youtube Channel Registrar Corp FDA News Blog
HomeDrugsU.S. FDA Active Pharmaceutical Ingredients (API)API Examples › U.S. FDA Regulations: Aprepitant

U.S. FDA Requirements: Aprepitant

Pharmaceutical / Drug Definition : Augments antiemetic activity of ondansetron (a 5-hydroxytryptamine3-receptor antagonist) and dexamethasone. Also inhibits cisplatin-induced emesis.

Registrar Corp assists Aprepitant companies with:

  • FDA Registration Aprepitant
  • FDA Listing Aprepitant
  • FDA Label Requirements and Exceptions Aprepitant
  • FDA Import Information Aprepitant
  • FDA Detentions Aprepitant (Aprepitant Entry Refusal)
  • General U.S. Food and Drug Administration Guidelines for:
       - Manufacturers Aprepitant (Aprepitant Suppliers)
       - Processors Aprepitant
       - Repackers Aprepitant
       - Relabelers Aprepitant
       - Exporters Aprepitant
       - Importers Aprepitant
For more information about Aprepitant, simply click below:




Live Help

 
U.S. FDA Regulations:

U.S. FDA Regulation: 21 C.F.R. Part 207


Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.
Home | About Us | News | Resources | Exhibitions | Seminars | Associations | Careers | Sitemap | Terms of Use © 2014 Registrar Corp
 
Food and Beverages | Drugs | Cosmetics | Medical Devices | Radiation-Emitting Electronic Devices | Color Additives | Tobacco